<DOC>
	<DOCNO>NCT02744391</DOCNO>
	<brief_summary>This study elucidate neurobiology slow LLD , identify novel therapeutic target depression , contribute development personalize treatment regimen LLD . The multimodal neuroimaging method detailed application provide information neurobiology aging-associated slow LLD molecular , structural , functional level analysis . These data fill crucial gap knowledge regard physiologic functional consequence dopamine depletion occur across lifespan individual without PD . Results project also allow u evaluate novel therapeutic approach LLD , could large public health ramification give prevalence , frequent treatment resistance , chronicity characteristic LLD . Even apart patient LLD , cognitive motor slow exact large public health burden term impair function increase morbidity mortality , burden grow population age . It critical develop treatment capable alter negative health trajectory associate slow order help older adult maintain independent function live longer increase quality life . Finally , PET MRI may prove critical understand neurobiology slow LLD , invasiveness expense limit role inform treatment decision clinical practice setting . For reason investigator also assess influence genetic moderator interleukin-6 ( IL-6 ) catechol-O-methyl-transferase ( COMT ) genotype baseline dopamine function response L-DOPA . This may facilitate identification high-risk individual likely benefit treatment intervention .</brief_summary>
	<brief_title>A Study L-DOPA Depression Slowing Older Adults</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Age &gt; 59 year DSM 5 nonpsychotic Major Depressive Disorder , Dysthymia , Depression Not Otherwise Specified Center Epidemiological Studies Depression ( CESD ) Rating Scale &gt; 9 Decreased processing speed ( define 0.5 SD ageadjusted norm Digit Symbol Test ) decrease gait speed ( defined average walk speed 15 ' course &lt; 1 m/s ) Willing capable providing inform consent comply study procedure Prefer treat standard treatment MDD , Dysthymia , Depression NOS ( e.g. , antidepressant medication psychotherapy ) Diagnosis substance abuse dependence ( exclude Tobacco Use Disorder ) within past 12 month History current psychosis , psychotic disorder , mania , bipolar disorder Diagnosis probable Alzheimer 's Disease , Vascular Dementia , PD Mini Mental Status Exam ( MMSE ) &lt; 25 HRSD â‰¥ 25 presence significant suicide risk Current recent ( within past 4 week ) treatment antidepressant , antipsychotic , dopaminergic agent , mood stabilizer History allergy , hypersensitivity reaction , severe intolerance LDOPA Acute , severe , unstable medical neurological illness Mobility limit osteoarthritis low extremity joint , symptomatic lumbar spine disease , history joint replacement surgery , history spine surgery Hypotension ( SBP &lt; 90 ) , hypertension ( SBP &gt; 150 DBP &gt; 90 ) , past stroke cause sensory movement deficit , cardiac arrhythmia , severe uncontrolled cardiovascular disease Having contraindication MRI scanning ( metal body ) unable tolerate scanning procedure History significant radioactivity exposure ( nuclear medicine study occupational exposure ) Presence clinically significant brain abnormality , significant anemia , insulin dependent diabetes , history cardiovascular disease , uncontrolled/untreated risk factor coronary artery disease</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>